External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology JSCO 2024
Roche and Genentech at

JSCO 2024

October 24 - October 26
Fukuoka, Japan
congress.jsco.or.jp
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 24 / Roche and Genentech
Phase I study of divarasib (GDC-6036) in Japanese patients with locally advanced or metastatic solid tumors with KRAS G12C mutations
Results from a Phase I study of divarasib in Japanese patients with advanced solid tumors.
Oncology Lung Cancer JSCO-2024
07:00 AM
Duration 8mins Venue 3 (Fukuoka International Conference Room 201+202)
Phase I study of divarasib (GDC-6036) in Japanese patients with locally advanced or metastatic solid tumors with KRAS G12C mutations
Kuboki Y, Murakami H, Kawazoe A, Katsuya Y, Nakagawa S, Yamagata R, Fueta M, Koyama T
Oncology | Lung Cancer

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.